PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Adrenaline - Anaphylaxis

PAD Profile : Adrenaline - Anaphylaxis

Keywords :
adrenaline auto-injectors, adrenaline auto injectors, allergic emergencies, anaphylactic shock, AAIs
Brand Names Include :
Epinephrine, Anapen, EpiPen, Jext, Emerade

Traffic Light Status

Status 1 of 1.

Status :
Green
Important
Formulations :
  • Auto-injector
Important Information :
Prescribe by brand. Injection technique is device-specific
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

No drugs returned.

Other Indications

No indications returned.

Additional Documents

Type
Document
Review Date
Patient resource
01 September 2022
Patient resource
01 September 2022
Patient resource
01 September 2022

Committee Recommendations

Date
Committee Name
Narrative
01 December 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands APC have agreed a variety of resources to support the safe and effective prescribing of adrenaline auto-injectors:

  • an Aide Memoire for Primary Care when prescribing adrenaline auto-injectors
  • guidance for the prescribing of appropriate quantities
  • a checklist / proforma for completion by secondary care when discharging adults or children following anaphylaxis
  • an AccuRx template

See below for these documents

The prescribing of Jext, EpiPen and Emerade are supported and should be prescribed by BRAND to ensure the patient receives the correct device.
Patients should receive regular device training. Patient support materials are also available below.

Associated BNF Codes

03. Respiratory System
03.04.03. Allergic emergencies
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More